FULC — Fulcrum Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $486.28m
- $272.17m
- $80.00m
- 57
- 28
- 98
- 65
Annual income statement for Fulcrum Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 8.82 | 19.2 | 6.34 | 2.81 | 80 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 80.4 | 100 | 119 | 113 | 102 |
| Operating Profit | -71.6 | -81.1 | -113 | -111 | -21.9 |
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -70.8 | -80.8 | -110 | -97.3 | -9.72 |
| Net Income After Taxes | -70.8 | -80.8 | -110 | -97.3 | -9.72 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -70.8 | -80.8 | -110 | -97.3 | -9.72 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -70.8 | -80.8 | -110 | -97.3 | -9.72 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -2.79 | -2.29 | -2.43 | -1.59 | -0.124 |